Table 3. Median time to event for patients with asymptomatic colorectal cancer in two trials.
| Immediate treatment | Delayed treatment | |||
|---|---|---|---|---|
| Outcome | n=84 | n=84 | Hazard ratio (95% CI) | P-value |
| Time to disease progression (months) | ||||
| Australasian trial | 13.0 | 12.0 | 1.11 (0.72–1.70) | 0.65 |
| Canadian trial | 7.7 | 8.4 | 0.89 (0.52–1.51) | 0.65 |
| Total | 10.2 | 10.8 | 1.01 (0.72–1.41) | 0.95 |
| Adjusteda | 1.08 (0.71–1.64) | 0.73 | ||
| Survival (months) | ||||
| Australasian trial | 15.5 | 11.9 | 1.08 (0.73–1.62) | 0.70 |
| Canadian trial | 11.9 | 10.2 | 1.07 (0.66–1.76) | 0.78 |
| Total | 13.0 | 11.0 | 1.08 (0.79–1.47) | 0.63 |
| Adjusteda | 1.15 (0.77–1.72) | 0.49 | ||
CI=confidence interval.
a
Adjusted for age, sex, weight, ECOG performance status, prior adjuvant chemotherapy, and baseline quality of life.